Gary S. Gillheeney, Sr. is the President and CEO of Organogenesis Holdings Inc. since December 2018. He has built a reputation for leading the company in the biotechnology sector, focusing on regenerative medicine. Born in 1962, Gary holds a Bachelor's...

Gary S. Gillheeney, Sr. is the President and CEO of Organogenesis Holdings Inc. since December 2018. He has built a reputation for leading the company in the biotechnology sector, focusing on regenerative medicine. Born in 1962, Gary holds a Bachelor's degree in Business Administration. Over the years, he has successfully grown the company’s revenue and guided key strategic decisions. In 2022, his total compensation reached approximately $6 million, reflecting both a solid base salary and performance bonuses which drive his focus on results. Gary's value as a leader is highlighted by his long-standing commitment to employee benefits, including health and insurance coverages that keep the workforce motivated. His strong ties to shareholder interests are seen in the stock options that align executives with the company’s success, enhancing long-term growth. Gary has always been a straightforward leader who emphasizes results over promises, making him an influential figure in the industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Organogenesis Holdings Inc. CEOs

O

Gary S. Gillheeny, Sr.

Ex-CEO of Organogenesis Holdings Inc.

Education

Bachelor's degree in Business Administration

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

March 1, 1962 - 63 years ago

CEO of Organogenesis Holdings Inc. for

2 years 4 months (Dec 2018 - May 2021)

Previous Experience

President and Chief Executive Officer of Organogenesis Holdings Inc.

Rivals

Competitors/colleagues of Gary S. Gillheeny, Sr.

Holdings

See how much did Gary S. Gillheeny, Sr. make over time.

As of 2023, Gary Gillheeney holds significant shares in Organogenesis, having built his wealth primarily through the company’s stock options. His insider trading reflects a stable approach; for example, in 2022, he received 1,655,381 shares as stock options that could...

As of 2023, Gary Gillheeney holds significant shares in Organogenesis, having built his wealth primarily through the company’s stock options. His insider trading reflects a stable approach; for example, in 2022, he received 1,655,381 shares as stock options that could increase his wealth based on company performance. At the end of 2023, he still holds over 1 million shares that are yet to vest, showing long-term commitment to the company. The value of these shares is tied closely to the company’s performance, aligning his interests with those of the shareholders. His holdings saw fluctuations in value during 2022, where strong performance led to increases, greatly benefiting him and emphasizing the direct connection between leadership, stockholder value, and personal wealth in the biotech space.

Total Stock Sold

$18.13M

ORGO

$18.13M

2,327,900 ORGO shares

What if they kept their stock?

If Gary S. Gillheeny, Sr. didn't sell their stock, today they would have:
Extra ORGO2,327,900 shares worth $8.05M.
This is -55.57% and $10.07M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Gary S. Gillheeny, Sr..

ORGO

708,215 shares

ORGO

Feb 19, 2025

Received

ORGO

$209.61K

ORGO at $3.43/share

Dec 13, 2024

Sale

ORGO

$936.19K

ORGO at $3.61/share

Dec 10, 2024

Sale

ORGO

$213.19K

ORGO at $3.59/share

Dec 5, 2024

Sale

ORGO

685,131 shares

ORGO

Feb 21, 2024

Received

ORGO

896,414 shares

ORGO

Feb 22, 2023

Received

ORGO

$1.37M

ORGO at $5.54/share

Jun 1, 2022

Sale

ORGO

$1.31M

ORGO at $5.77/share

May 26, 2022

Sale

ORGO

$1.13M

ORGO at $5.73/share

May 23, 2022

Sale

ORGO

$1.52M

ORGO at $5.76/share

May 18, 2022

Sale

Compensation History

See how much did Gary S. Gillheeny, Sr. make over time.

Gary S. Gillheeney's compensation has significantly varied over the years at Organogenesis. In 2021, his total compensation was about $4.4 million, which included a base salary of approximately $834,637 and a bonus of $699,200. The 2022 fiscal year saw a hike in his total earnings to around $6 million, reflecting a robust bonus and long-term incentives. Unique to his position, there were no stock grants that vested in those years, emphasizing the company's philosophy to motivate executives through cash compensation tied to performance rather than equity alone. His compensation structure illustrates a balance between immediate rewards and long-term performance goals, designed to encourage better results and shareholder returns.

Year

2021

Total Compensation

$1.61M

Salary

$834.64K

Board Justification

The compensation philosophy is designed to align compensation with business objectives, individual performance, and the interests of stockholders, motivating and rewarding high levels of performance.

Bonus

$699.20K

Board Justification

Discretionary bonuses earned by our NEOs for fiscal year 2021.

Other

$76.68K

Board Justification

Includes costs related to a leased automobile, tax gross-ups, group term life insurance, long-term disability insurance premiums, and employer matching contributions under the 401(k) plan.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2021 as the focus is on cash compensation and bonuses.

Performance Metrics

Compensation is determined based on individual performance metrics and company performance.

Other Organogenesis Holdings Inc. CEOs

Here are other CEOs of Organogenesis Holdings Inc.

David C. Francisco

CEO of Organogenesis Holdings Inc.

February 2021 - Present